Review
Endocrinology & Metabolism
Per Karkov Cramon, Jakob Bue Bjorner, Mogens Groenvold, Victor Brun Boesen, Steen Joop Bonnema, Laszlo Hegedus, Ulla Feldt-Rasmussen, Ase Krogh Rasmussen, Torquil Watt
Summary: Patient-reported outcomes (PROs) are increasingly used in clinical practice to improve clinical care. However, successful implementation of PROs requires addressing barriers and challenges.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Mallorie H. Fiero, Jessica K. Roydhouse, Vishal Bhatnagar, Ting-Yu Chen, Bellinda L. King-Kallimanis, Shenghui Tang, Paul G. Kluetz
Summary: Time-to-event endpoints for patient-reported outcomes, such as time to deterioration of symptoms or function, have unique considerations and challenges in cancer clinical trials. Analytical decisions using the estimand framework can help answer specific clinical questions, while the complexity and burdens associated with measuring time to deterioration make it problematic for widespread use. Instead, analyzing at pre-specified relevant time-points might be a better approach for trials focusing on comparative symptom or functional benefits.
Article
Oncology
Mahmut Gumus, Chieh- Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidaris, Medha Sasane, Keri J. S. Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer
Summary: According to the EMPOWER-Lung 1 trial, cemiplimab provides longer survival and improved quality of life compared to platinum-doublet chemotherapy in patients with advanced NSCLC with PD-L1 >= 50%, while reducing symptom burden.
Article
Oncology
Alicia K. Morgans, Simrun Grewal, Zsolt Hepp, Rupali Fuldeore, Shardul Odak, Cynthia Macahilig, Alicia C. Shillington, Guru Sonpavde
Summary: The patterns of care and attrition of la/mUC patients eligible for systemic therapy following PD-1/L1 inhibitors are not well understood. This study found that a minority of patients received subsequent therapy after discontinuation of PD-1/L1 inhibitor therapy, and the outcomes were poor. The burden of symptoms and caregiving was high among these patients.
CLINICAL GENITOURINARY CANCER
(2022)
Review
Pharmacology & Pharmacy
Jinhua Liu, Zichao Chen, Yaqun Li, Wenjie Zhao, JiBiao Wu, Zhen Zhang
Summary: Programmed death protein 1 (PD1) is an important immune checkpoint on T cells that plays a crucial role in downregulating the immune system and promoting self-tolerance, while its ligand, programmed cell death ligand 1 (PDL1), is overexpressed in malignant tumor cells, contributing to immune evasion and treatment failure. Despite the clinical efficacy of PD1/PDL1 inhibitors in many tumors, some patients may develop drug resistance, highlighting the need for further research into improving targeted therapies and understanding the associated safety issues.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Anika Varma, Jennifer Weinstein, Jamison Seabury, Spencer Rosero, Ellen Wagner, Christine Zizzi, Elizabeth Luebbe, Nuran Dilek, Michael McDermott, John Heatwole, Lawrence Saubermann, Larissa Temple, Scott Rogoff, Chad Heatwole
Summary: This study aimed to identify the most prevalent and impactful symptoms in patients with Crohn's disease (CD) and to determine the modifying factors associated with a higher disease burden in CD.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Meaghann S. Weaver, Shana S. Jacobs, Janice S. Withycombe, Jichuan Wang, Katie A. Greenzang, Justin N. Baker, Pamela S. Hinds
Summary: The results of this cohort study suggest that there is alignment between proxy caregiver reports and children's self-reports of symptoms. Proxy reports can serve as a guide to care when the child is unable to self-report.
Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Stephanie Alimena, Lauren Philp, Endel John Orav, Mackenzie W. Sullivan, Marcela Del Carmen, Annekathryn Goodman, Whitfield B. Growdon, Amy Bregar, Eric Eisenhauer, Rachel Clark Sisodia
Summary: While no obvious memory issues were discovered with serial administration of patient-reported outcome measures, rates of adverse emotional symptoms such as depression, tension, and worry decreased after chemotherapy. Chemotherapy can have some impact on patients' social lives. Further research with a larger cohort is needed to explore the phenomenon of chemotherapy-related cognitive impairment.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Urology & Nephrology
Odinachi Moghalu, John T. Stoffel, Sean P. Elliott, Blayne Welk, Chong Zhang, Angela Presson, Jeremy Myers
Summary: Increased time after spinal cord injury is associated with changes in bladder management, symptoms, and satisfaction. Clean intermittent catheterization decreases while indwelling catheter increases over time. The study found that longer time from injury is associated with reduced urinary symptoms and improved bladder-related satisfaction.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Clarisse Audigier-Valette, Bogdan Zurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishio, Emmanuel de la Mora Jimenez, Krysztof Lesniewski-Kmak, Istvan Albert, Samreen Ahmed, Konstantinos Syrigos, John R. Penrod, Yong Yuan, Steven Blum, Faith E. Nathan, Xiaowu Sun, Alejandro Moreno-Koehler, Fiona Taylor, Kenneth John O'Byrne
Summary: The study demonstrated that in treatment-naive patients with advanced NSCLC, nivolumab plus ipilimumab showed delayed deterioration and numerical improvement in symptoms and health-related quality of life compared to chemotherapy.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Adrienne H. Kovacs, Gerald Lebovic, Stavroula Raptis, Samuel Blais, Christopher A. Caldarone, Nagib Dahdah, Frederic Dallaire, Christian Drolet, Jasmine Grewal, Camille L. Hancock Friesen, Edward Hickey, Gauri Rani Karur, Paul Khairy, Benedetta Leonardi, Michelle Keir, Brian W. McCrindle, Syed Najaf Nadeem, Ming-Yen Ng, Ashish H. Shah, Edythe B. Tham, Judith Therrien, Andrew E. Warren, Isabelle F. Vonder Muhll, Alexander Van de Bruaene, Kenichiro Yamamura, Michael E. Farkouh, Rachel M. Wald
Summary: This study explored the relationship between pulmonary regurgitation and quality of life and health status in adults with Tetralogy of Fallot (TOF), and found that with advancing age, patients reported more problems in mobility and pain or discomfort. Factors associated with superior patient-reported outcomes include race, syndrome, employment, and left ventricular function, while being asymptomatic was found to have the greatest impact on quality of life and health status.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Gastroenterology & Hepatology
John E. Pandolfino, Dustin A. Carlson, Josie McGarva, Peter J. Kahrilas, Michael Vaezi, David Katzka, Tiffany H. Taft
Summary: The study developed a new Achalasia Patient-Reported Outcomes (APRO) Questionnaire, identified three subscales through investigation of patients with normal motility and achalasia, and found that symptom anxiety and hypervigilance moderate the relationship between APRO and quality of life.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Surgery
Danny Mou, Claire E. E. DeVries, Nena Pater, Lotte Poulsen, Dennis J. S. Makarawung, Marinus J. Wiezer, Ruben N. van Veen, Maarten M. Hoogbergen, Jens A. Sorensen, Anne F. Klassen, Andrea L. Pusic, Ali Tavakkoli
Summary: This study compared differences in eating behavior, eating-related distress, and eating-related symptoms between patients undergoing laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) using a newly developed and validated patient-reported outcome measure (PROM). The LRYGB patients had better weight loss after surgery, but scored worse on post-prandial symptoms when compared to LSG patients.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2021)
Article
Endocrinology & Metabolism
Eliza B. Geer, Roberto Salvatori, Atanaska Elenkova, Maria Fleseriu, Rosario Pivonello, Przemyslaw Witek, Richard A. Feelders, Marie Bex, Stina W. Borresen, Soraya Puglisi, Beverly M. K. Biller, Fredric Cohen, Francesca Pecori Giraldi
Summary: The study demonstrated significant improvements in skin symptoms and patient-reported quality of life and depression symptoms in patients with CS treated with levoketoconazole during the maintenance phase.